Background and Aims: Mucosal healing and control of intestinal mucosal inflammation are important treatment goals for maintaining clinical remission in ulcerative colitis [UC] patients. Here, we investigated the efficacy of linked colour imaging [LCI], a novel endoscopic enhancement system, for diagnosing mucosal inflammation in UC patients. Methods: All examinations were carried out with a LASEREO endoscopic system [FUJIFILM Co., Tokyo, Japan]. Fifty-two patients with UC were enrolled, and 193 areas assessed by LCI were examined. LCI patterns were classified as; A, no redness; B, redness with visible vessels; and C, redness without visible vessels. Regions of interest [ROIs] were set at biopsy sites, and the red colour in the ROI was calculated from the Commission internationale de l'éclairage [CIE] color space and digitized [LCI-index]. Biopsy specimens were taken at each ROI and evaluated with Matts histopathological grade. Thirty months was defined as the time interval between endoscopic diagnosis and relapse of UC. Results: Interobserver agreement for LCI classification was excellent between an expert and nonexperts. Among areas with a Mayo endoscopic subscore of 0, 41.8% and 4.6% were classified as LCI-B and LCI-C, respectively. Among areas with a Mayo endoscopic subscore of 1, 60.5% and 34.6% were classified as LCI-C and LCI-B, respectively. The LCI index strongly correlated with the histopathological Matts score. Non-relapse rates significantly correlated with LCI classification [p = 0.0055], but not with Mayo endoscopic subscore [p = 0.0632].
Assessment of Endoscopic Mucosal Healing of

Introduction
Since mucosal healing has been reported as a key treatment goal in inflammatory bowel disease [IBD] , predicting sustained clinical remission and colectomy-free survival, 1 precise and detailed realtime assessment of the superficial mucosal layer is more important than ever for the medical management of IBD patients. The precise assessment of intestinal inflammation has been reported to be of pivotal importance for the management of IBD patients, 2 and advanced endoscopic imaging techniques, including magnification endoscopy 3, 4 and dye-based chromoendoscopy, [5] [6] [7] [8] [9] have provided evidence of the clinical benefit of surveillance colonoscopy for detecting mucosal dysplasia and colitis-associated cancer in ulcerative colitis [UC] patients.
In one of the earliest studies investigating dye-less chromoendoscopy for the assessment of mucosal inflammation associated with UC, the mucosal vascular pattern in patients with asymptomatic or mildly active UC was analysed using narrow-band imaging [NBI] and high-definition [HD] white-light endoscopy. 10 The areas with obscure mucosal vascular pattern on NBI exhibited increased acute inflammatory cell infiltrate, goblet cell depletion, and basal plasmacytosis, and the evaluation yielded a more precise determination of acute microscopic inflammation in patients with quiescent UC. The typical findings of active and quiescent UC on NBI have been summarized as well. 11 Dye-based chromoendoscopy with methylene blue not only permitted a more accurate diagnosis of the extent and severity of inflammatory activity in UC compared with conventional colonoscopy, 12 but also significantly improved the early detection of intraepithelial neoplasia and colitis-associated cancer. 12 However, data on the relevance of digital computer-based colour programs for the assessment of mucosal inflammation in UC patients are limited. Recently, a study including 78 IBD patients who underwent either HD white-light endoscopy or HD endoscopy with i-scan demonstrated that i-scan allows a considerably improved prediction of disease extent and disease activity compared with white-light endoscopy. 13 However, a study using Fujinon Intelligent Color Enhancement [FICE] showed that it was not helpful for improving the detection or delineation of ulcers and erosions in Crohn's disease.
14 Autofluorescence imaging [AFI] is reported to be useful for evaluating mucosal inflammation of UC patients. 15 It was demonstrated that the green colour component of the AFI image is correlated with mucosal inflammation.
Linked colour imaging [LCI] has been recently developed using a laser endoscopic system [Fujifilm Co., Tokyo, Japan] to provide an expanded colour range, resulting in reddish and whitish colours becoming redder and whiter, respectively. 16 Although utility of LCI for the detection of Helicobacter pylori infection in the gastric mucosa has been reported, 17 its utility for the evaluation of colonic mucosa in UC patients has not been investigated. In the present study, we conducted a pilot investigation of the application of LCI for diagnosing colonic mucosal conditions in patients with UC.
Materials and Methods
Patients
Patients with established UC were enrolled in this pilot study between June 1 2014 and March 31 2016. All patients were attending the gastroenterology outpatient clinic at the Kyoto Prefectural University of Medicine Hospital. A total of 52 patients were enrolled in this study, and a total of 193 areas of colonic mucosa were evaluated by both White Light Imaging [WLI] and LCI. The protocol of this study was approved by the Ethics Committee of the Kyoto Prefectural University of Medicine, and written informed consent was obtained from all patients before the original procedures were performed. This study was conducted in accordance with the ethical principles associated with the Declaration of Helsinki and registered in the University Hospital Medical Network Clinical Trials Registry [UMIN000017990].
Assessment of disease activity
Clinical and endoscopic disease activities were determined using the Lichtiger Colitis Activity Index [LCAI] 18 for clinical activity, and the Mayo endoscopic subscore for endoscopic activity. All enrolled patients were in clinical remission (defined as a LCAI score of 4 or below).
Endoscopic image
All examinations were carried out with a high-definition EG-L590WR endoscope as part of the LASEREO endoscopic system [Fujifilm Medical Co., Tokyo, Japan]. In brief, this LASEREO system uses a semi-conductor laser as the light source and has narrow-band light observation functions, blue laser imaging [BLI] and LCI, without a customized optical filter. It uses two types of lasers: 410-nm and 450-nm wavelengths. Both bandwidths are <2 nm, in contrast to the bandwidth for NBI [30 nm] . 19 The laser with a 450-nm wavelength produces irradiated phosphor with an illumination similar to that produced by a xenon lamp. The combination of strong laser light with a wavelength of 450-nm and fluorescent light provides illumination that is almost equivalent to that of WLI. LCI is a new image-enhanced technology that is intended to enhance slight colour differences in the red region of the mucosa. This mode is based on the image captured under similar light conditions in BLI-bright mode; however, further post-image processing is later applied so that the slightly reddish colour becomes much redder, and the slightly whitish colour much whiter, than the colours appear under WLI. Ultimately, LCI improves the ability of the observer to recognize slight differences in mucosal colour, such as those arising from inflammation or atrophy, compared with conventional WLI. LCI improves the recognition of slight differences in mucosal colour by reallocating the acquired colour information on a colour space. LCI patterns were classified as A, no redness; B, redness with visible vessels; and C, redness without visible vessels [ Figure 1 ]. The concept of this classification is based on the intensity of mucosal redness. Because the LCI system can enhance mucosal redness, this classification is expected to diagnose mucosal redness effectively. All of the 193 areas were diagnosed using both the LCI classification and the Mayo endoscopic subscore.
Participating endoscopists and diagnostic evaluation
Three endoscopists who were blinded to the background of endoscopic image and clinical data evaluated all endoscopic images. None of them performed any of the colonoscopies in this study. One was an expert endoscopist [expert A] who had previously performed >5000 conventional colonoscopies, while the other two were nonexpert endoscopists [non-experts B and C] who had previously performed <1000 conventional colonoscopies. These three endoscopists evaluated the images from each endoscopic modality [WLI and LCI], which consisted of endoscopic pictures from 50 areas randomly arranged on one slide and displayed independently from the images of the other endoscopic modality. Images from WLI were evaluated by Mayo endoscopic subscore, and images from LCI were classified as type A to C as described above.
Histopathological assessment
Inflammation in biopsy specimens was evaluated according to the Matts histopathological grade [1 = normal appearance; 2 = some infiltration of the mucosa or lamina propria with either round cells or polymorphs; 3 = much cellular infiltration of the mucosa, lamina propria, and submucosa; 4 = presence of crypt abscesses, with much infiltration of all layers of the mucosa; 5 = ulceration, erosion or necrosis of the mucosa, with cellular infiltration of some or all of its layers] 20 by one expert pathologist. The biopsies were collected from the same sites that were subjected to LCI classification.
Definition of ulcerative colitis relapse
Relapse of UC was defined as the need for more aggressive medication for UC due to aggravation or clinical symptoms [LCAI score of ≥5], or aggravation of endoscopic findings [higher Mayo endoscopic subscore than previous endoscopic examination]. The LCI classification of each patient was defined by the most severe area of LCI classification.
Objective evaluation
Redness of the lesion in the region of interest [ROI] 
Results
Patient baseline demographic variables
The characteristics of the 52 patients who were enrolled in this study are shown in Table 1 The median follow-up time of patients in the non-relapse group was 16.0 months and in relapse group was 10.0 months .
In this study, we determined the interval as 30 months for follow-up patients from the point of the diagnostic endoscopy of LCI classification and LCI index.
Validation of endoscopic findings
The kappa values for the interobserver variability across the three endoscopists in diagnosing the Mayo endoscopic subscore by WLI were excellent. The kappa values for the interobserver variability across the three endoscopists in diagnosing the endoscopic LCI classification were also excellent [ 
The relationship between the Mayo endoscopic subscore and the LCI classification
The summary of the endoscopic diagnoses for the whole 193 areas is shown in Table 3 Figure 2 ]. These results indicate that endoscopic LCI classification was independent of the Mayo endoscopic subscore. In particular, it was possible to subdivide samples with a Mayo endoscopic subscore of 1 into LCI-B and -C classifications based on mucosal redness recognized by LCI.
The relationship between endoscopic LCI classification and histopathological Matts classification
In areas classified as LCI-A, most of the histopathological assessments from biopsy specimens were Matts grade 2 [94.0%]. Among areas classified as LCI-B, 78.8% were Matts grade 2, and 18.1% were Matts grade 3 [ Figure 3 ]. Among areas classified as LCI-C, 35.1% were Matts grade 2. These results indicate that endoscopic LCI classification reflects the inflammatory cell infiltration into the colonic mucosa, as assessed histopathologically with the Matts grading.
Objective evaluation of LCI images
The correlation between endoscopic LCI classification and the LCI-index is shown in Figure 4A . The LCI-index levels of LCI-A, LCI-B and LCI-C were 16.01 ± 7.74, 36.53 ± 7.48 and 44.89 ± 6.1, respectively. These LCI-index levels were strongly correlated with the endoscopic LCI classification [p < 0.001]. The LCI-index levels at the collection sites of biopsy specimens with histological Matts grade 2, 3 and 4 were 30.00 ± 13.46, 42.78 ± 9.02 and 46.50 ± 2.57, respectively. Although the LCIindex level at the collection sites of biopsies of Matts grade 2 was widely distributed, the LCI index was correlated to Matts grade [p = 0.001] [ Figure 4B ].
Ulcerative colitis relapse
Over the 30-month study period, 14 patients experienced clinical relapse of UC. Among these 14 patients, 64.3% [9/14] were diagnosed as LCI-C, 35.7% [5/14] as LCI-B, and none as LCI-A [ Figure 5A ]. The non-relapse rates of patients classified as LCI-B and LCI-C were statistically significantly lower than the non-relapse rate of patients classified as LCI-A, and it had great correlation with LCI classification [p = 0.0055]. On the other hand, among these 14 patients, 28.6% [4/14] were diagnosed as Mayo endoscopic subscore 0, 57.1% [8/14] as Mayo endoscopic subscore 1, and 14.3% [2/14] as Mayo endoscopic subscore 2. The non-relapse rates did not have a statistically significant relationship to the Mayo endoscopic subscore [p = 0.0632]. The relationship between the LCI-index and relapse is shown in Figure 5C 
Discussion
In the present study, we investigated the utility of LCI, a novel endoscopic enhancement system, for patients in clinical remission with UC. The colonic mucosal redness enhanced by LCI correlated with mucosal inflammation and was associated with UC relapse. Furthermore, the LCI-index enabled an objective approach for investigating mucosal redness and inflammation. To our knowledge, this study is the first to evaluate the colonic mucosa of UC patients using LCI, and it suggests that LCI can be a useful approach for assessing the pathophysiology of UC.
It has been reported that not only clinical remission, but also the achievement of endoscopic mucosal healing [MH] , is a predictive factor of better long-term clinical outcomes (such as lower risk of colectomy and avoidance of colitis-associated cancer) in UC patients. 23, 24 The follow-up study of the Active UC Trials [ACT-1, 2] revealed that MH after 8 weeks of infliximab treatment was correlated with better clinical outcomes, including avoidance of colectomy. 25 Therefore, achieving endoscopic MH has been proposed as a new therapeutic goal for the treatment of UC. However, no standardized criteria for the evaluation of disease severity and definitions of MH have been established to date. 1 Although previous clinical studies have defined MH as a Mayo endoscopic subscore of 0 or 1, 25,26 the long-term outcome for patients with a Mayo endoscopic subscore of 0 was markedly better than that of patients with a Mayo endoscopic subscore of 1. In the ACT-1, two clinical studies, the remission rate after 54 weeks was 73% in patents with a Mayo endoscopic subscore of 0, but 27 Yokoyama et al. also reported that 5-year relapse-free rates for patients with Mayo endoscopic subscores of 0 and 1 were 78% and 40% respectively. 28 Nakaral et al. reported that patients with a Mayo endoscopic subscore of 1 had a significantly higher long-term risk of clinical relapse than patients with a Mayo endoscopic subscore of 0. 29 Based on these reports, a Mayo endoscopic subscore 1 is not an appropriate indicator of mucosal remission because of the high relapse rate. Even the patients with a Mayo endoscopic subscore of 0 showed some relapse. Taken together, these findings suggest that new endoscopic criteria other than the Mayo endoscopic subscore are needed for predicting the prognosis and recognizing the pathophysiology of UC.
In the present study, we classified endoscopic images observed by LCI into three categories-LCI-A, -B, and -C-based on their degree of mucosal redness and visible vessels. The kappa values reflecting the rates of diagnostic concordance for LCI classifications between expert and non-experts or between two non-experts were all >0.9, indicating excellent agreement. Additionally, the LCI classification was independent of the Mayo endoscopic subscore, particularly in that it could subdivide areas with Mayo endoscopic subscore 1. Furthermore, in this study, we demonstrated that LCI classification is a predictor of UC relapse, as patients classified as LCI-A had a higher non-relapse rate statistically compared with those classified as LCI-B and -C. As the Mayo endoscopic subscore did not show a statistically significant correlation with non-relapse ratio, the LCI classification could be superior to the Mayo endoscopic subscore in predicting relapse in UC patients. These results indicate that the LCI classification system may make possible a novel approach for evaluating the colonic mucosa of UC patients as an alternative to the Mayo endoscopic subscore. The LCI classification also reflected mucosal inflammation as assessed by the Matts histopathological grading. Endoscopic findings have been previously shown to correlate with Matts histopathological grade. 30 Mucosal evaluation of UC patients, using high-magnification endocytoscopy, has also been found to correlate with the Matts histopathological grade. 31, 32 The level of mucosal redness captured by LCI can be evaluated objectively and effectively because the mucosal redness is strongly enhanced compared with WLI. This study is the first trial to investigate the digitization of colonic mucosal redness in UC patients using LCI images as a LCI-index. We demonstrated a strong correlation between endoscopic LCI classification and the LCI-index, which indicates that endoscopic LCI classification is objective and widely applicable. The average of the LCI-index for the patients in the nonrelapse group was statistically lower than that in the relapse group. Further investigation and instrument development will be necessary in order to digitize mucosal redness in real time during endoscopic procedures. This approach to the evaluation of colonic mucosa in UC patients may be more effective and objective than approaches used to date.
Conclusion
This investigation was a pilot study seeking to evaluate the usefulness of LCI for UC, its major limitations being its small size and restriction to a single centre. A multi-institutional study with a large number of patients is now ongoing [UMIN000017990]. In conclusion, LCI may be a novel approach for the evaluation of colonic mucosa and predictive of the outcome for UC patients. 
